GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » PE Ratio (TTM)

GOVX (Geovax Labs) PE Ratio (TTM) : At Loss (As of Dec. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-12), Geovax Labs's share price is $2.44. Geovax Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.24. Therefore, Geovax Labs's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Geovax Labs's PE Ratio (TTM) or its related term are showing as below:

GOVX' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



GOVX's PE Ratio (TTM) is ranked worse than
100% of 246 companies
in the Biotechnology industry
Industry Median: 27.435 vs GOVX: At Loss

Geovax Labs's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.91. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.24.

As of today (2024-12-12), Geovax Labs's share price is $2.44. Geovax Labs's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.24. Therefore, Geovax Labs's PE Ratio without NRI for today is At Loss.

Geovax Labs's EPS without NRI for the three months ended in Sep. 2024 was $-0.91. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.24.

Geovax Labs's EPS (Basic) for the three months ended in Sep. 2024 was $-0.91. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-9.24.


Geovax Labs PE Ratio (TTM) Historical Data

The historical data trend for Geovax Labs's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs PE Ratio (TTM) Chart

Geovax Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Geovax Labs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Geovax Labs's PE Ratio (TTM)

For the Biotechnology subindustry, Geovax Labs's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Geovax Labs's PE Ratio (TTM) falls into.



Geovax Labs PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Geovax Labs's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=2.44/-9.240
=At Loss

Geovax Labs's Share Price of today is $2.44.
Geovax Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Geovax Labs  (NAS:GOVX) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Geovax Labs PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Geovax Labs's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs Business Description

Traded in Other Exchanges
N/A
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Executives
David A Dodd director C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds officer: Chief Financial Officer TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Mckee Kelly T. Jr. officer: Chief Medical Officer 233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
Jayne Morgan director 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey officer: VP, Business Development 16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas director 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr director 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally director
Farshad Guirakhoo officer: Sr VP, Research & Development 39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi director 10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson other: Chair, Scientific Adv Brd 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman officer: VP, Research & Development 1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas director 123 JOAN DRIVE, BARRINGTON IL 60010